- Home
- CROX vs MMED Comparison
CROX vs MMED Comparison
Compare CROX & MMED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CROX | MMED |
|---|---|---|
| Founded | 1999 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 5.5B |
| IPO Year | 2005 | 2025 |
Fundamental Metrics
Financial Performance| Metric | CROX | MMED |
|---|---|---|
| Price | $122.11 | $20.45 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 10 |
| Target Price | ★ $99.90 | $22.56 |
| AVG Volume (30 Days) | 1.0M | ★ 1.2M |
| Earning Date | 04-30-2026 | 06-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.83 | N/A |
| Revenue | ★ $4,040,647,000.00 | $3,102,000,000.00 |
| Revenue This Year | $2.01 | $15.99 |
| Revenue Next Year | $2.60 | $10.00 |
| P/E Ratio | $18.02 | ★ N/A |
| Revenue Growth | N/A | ★ 14.25 |
| 52 Week Low | $73.21 | $10.65 |
| 52 Week High | $141.28 | $20.88 |
Technical Indicators
Market Signals| Indicator | CROX | MMED |
|---|---|---|
| Relative Strength Index (RSI) | 39.34 | 68.18 |
| Support Level | $116.74 | $10.68 |
| Resistance Level | $128.89 | $20.88 |
| Average True Range (ATR) | 4.43 | 0.90 |
| MACD | -1.67 | -0.03 |
| Stochastic Oscillator | 5.37 | 91.83 |
Price Performance
Historical ComparisonAbout CROX Crocs Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable operating segments of the company are the Crocs Brand and the HEYDUDE Brand. The company derives maximum revenue from the Crocs brand segment.
About MMED MiniMed Group Inc. Common Stock
Minimed Group Inc is a scaled medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. It serves PWD who require intensive insulin therapy, which represents all people with T1D and a subset of those with T2D. The company's platform of simple and clinically effective solutions for PWD requiring insulin therapy includes Automated Insulin Delivery (AID) Systems and Smart Multiple Daily Injection (MDI) Systems. It derives revenue from the sale of products focused on diabetes management, including insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens. Geographically, it operates in the USA and the Rest of World, with the majority of revenue derived from the Rest of World.